shutterstock_1997869478_pla2na

Pla2na / Shutterstock.com

7 April 2022Sarah Gibbs

G 2/21: how to support inventive steps in patentability

Post-published evidence can be crucial to establishing patentability. G 2/21, the European Patent Office (EPO)’s referral to the Enlarged Board of Appeal (EBA) on the question of whether post-published evidence can be used to support the concept of “inventive step”.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

CRISPR: the shifting sands of patentability

12 November 2015 The patentability of any claims directed to the use of CRISPR technology in human embryo-like structures and human reproductive cells is far from certain, as Duncan Ribbons and Maeve Lynch of Redd explain.

Europe v US: the patentability of diagnostic claims

17 September 2015 Researchers should keep in mind that broad claims applying the discovery of a biomarker and disease correlation are currently patentable in Europe but not in the US. Andrew Carridge and Neil Thornton of Reddie & Grose report.

More on this story

CRISPR: the shifting sands of patentability

12 November 2015 The patentability of any claims directed to the use of CRISPR technology in human embryo-like structures and human reproductive cells is far from certain, as Duncan Ribbons and Maeve Lynch of Redd explain.

Europe v US: the patentability of diagnostic claims

17 September 2015 Researchers should keep in mind that broad claims applying the discovery of a biomarker and disease correlation are currently patentable in Europe but not in the US. Andrew Carridge and Neil Thornton of Reddie & Grose report.

More on this story

CRISPR: the shifting sands of patentability

12 November 2015 The patentability of any claims directed to the use of CRISPR technology in human embryo-like structures and human reproductive cells is far from certain, as Duncan Ribbons and Maeve Lynch of Redd explain.

Europe v US: the patentability of diagnostic claims

17 September 2015 Researchers should keep in mind that broad claims applying the discovery of a biomarker and disease correlation are currently patentable in Europe but not in the US. Andrew Carridge and Neil Thornton of Reddie & Grose report.

More features

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

GSK triumphs in EPO appeal, revoking Pfizer patent

China’s new policies on foreign investment in healthcare and biotech

Startup CFO’s betrayal is a lesson in preparing for the worst

LSPN Fall: Gilead GC shares top drafting tips

How post-filing data rescued Novo Nordisk’s Ozempic patent in China

How to navigate patent term adjustment in China

‘This is a big problem’: The CRISPR controversy and the ‘mess’ at the heart of the EPO’s appeals boards